119011-56-2

Basic information

• Product Name: 7-Chloro-2-(Methylsulfanyl)-[1,3]thiazolo[4,5-d]pyriMidine
• Synonyms: 7-Chloro-2-(Methylsulfanyl)-[1,3]thiazolo[4,5-d]pyriMidine;7-Chloro-2-(Methylthio)thiazolo[4,5-d]pyriMidine;7-Chloro-2-methylsulfanyl-thiazolo[4,5-d]pyrimidine
• CAS NO: 119011-56-2
• Molecular Formula: C₆H₄ClN₃S₂
• Molecular Weight: 217.69906
• Mol File: 119011-56-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7-Chloro-2-(Methylsulfanyl)-[1,3]thiazolo[4,5-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Chloro-2-(Methylsulfanyl)-[1,3]thiazolo[4,5-d]pyriMidine(119011-56-2)
• EPA Substance Registry System: 7-Chloro-2-(Methylsulfanyl)-[1,3]thiazolo[4,5-d]pyriMidine(119011-56-2)

Safety Data

• Hazardous Substances Data: 119011-56-2(Hazardous Substances Data)

Usage

Description

7-Chloro-2-(Methylsulfanyl)-[1,3]thiazolo[4,5-d]pyrimidine, with the CAS number 119011-56-2, is a chemical compound that serves as an important intermediate in the synthesis of various pharmaceutical agents. It is characterized by its unique molecular structure, which includes a thiazolo[4,5-d]pyrimidine core with a chlorine atom at the 7th position and a methylsulfanyl group at the 2nd position.

Uses

Used in Pharmaceutical Industry:
7-Chloro-2-(Methylsulfanyl)-[1,3]thiazolo[4,5-d]pyrimidine is used as a key intermediate in the synthesis of 2,7-diamino-thiazolo[4,5-d]pyrimidine analogs. These analogs are known for their anti-tumor properties, specifically as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. By inhibiting the activity of EGFR, these analogs can help in the treatment of various types of cancer by preventing the uncontrolled cell growth and proliferation associated with tumor development.
Additionally, 7-Chloro-2-(Methylsulfanyl)-[1,3]thiazolo[4,5-d]pyrimidine is used in the preparation of thiazolopyrimidines and thienopyrimidines. These compounds act as antagonists of CCR2b receptors, which play a crucial role in chemokine-mediated diseases. By blocking the CCR2b receptors, these antagonists can help in the treatment of various inflammatory and immune disorders, as well as other conditions related to chemokine signaling.

Upstream product

• 1228102-96-2 ethyl 4-formamido-2-(methylthio)thiazole-5-carboxylate 
• 39736-29-3 ethyl 4-amino-2-(methylthio)thiazol-5-carboxylate 
• 119011-50-6 2-(methylthio)thiazolo[4,5-d]pyrimidin-7(4H)-one 
• 39736-30-6 4-amino-2-(methylsulfanyl)-1,3-thiazole-5-carboxamide 
• 39736-28-2 2-methylmercapto-4-amino-5-cyanothiazole 
• 119011-50-6 2-(Methylthio)thiazolo<4,5-d>pyrimidin-7(6H)-on 

Downstream Products

• 1228102-97-3 N-(3-(4-methoxybenzyloxy)phenyl)-2-(methylthio)thiazolo[4,5-d]pyrimidin-7-amine 
• 1228103-53-4 N-(3-(4-methoxybenzyloxy)phenyl)-2-(4-methylpiperazin-1-yl)thiazolo[4,5-d]pyrimidin-7-amine 
• 1228102-66-6 3-(2-(4-methylpiperazin-1-yl)thiazolo[4,5-d]pyrimidin-7-ylamino)phenol trifluoroacetic acid 
• 871231-11-7 (3-chloro-4-fluoro-phenyl)-(2-methylsulfanyl-thiazolo[4,5-d]pyrimidin-7-yl)-amine 

Relevant articles and documents

NOVEL BICYCLIC HETEROCYCLIC COMPOUND

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention is for the anti-inflammatory compounds that have an inhibitory activity against protein tyrosine kinases and their pharmaceutical composition(s) containing the compound as the active ingredient. Since the compounds of the present invention can inhibit multiple protein kinases associated with inflammatory diseases and immune disorders, they are useful for their prevention or treatment.

CHEMICAL COMPOUNDS

The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, X4, Ra, p, R1,Z,Y, R2, R3 and R4 are as d